Table 4 Univariate analysis of 5-year survival

Age

< 60

19 (63.33)

30 (44.78)

4.912

0.027

≥ 60

11 (36.67)

37 (55.22)

Sex

Male

24 (80.00)

50 (74.63)

0.056

0.813

Female

6 (20.00)

17 (25.37)

Tumor diameter

< 4.0

19 (63.33)

29 (43.28)

6.681

0.009

≥ 4.0

11 (36.67)

38 (56.72)

Tumor location

Gastric body

3 (10.00)

11 (16.42)

2.503

0.286

Gastric antrum

20 (66.67)

48 (71.64)

Gastric fundus

7 (23.33)

8 (11.94)

Operation method

Distal gastrectomy

20 (66.67)

46 (68.66)

1.81

0.405

Proximal gastrectomy

6 (20.00)

10 (14.93)

Total gastrectomy

4 (13.33)

11 (16.42)

Clinicopathologic stage

I–II

23 (76.67)

24 (35.82)

22.32

< 0.001

III–IV

7 (23.33)

43 (64.18)

Differentiated degree

Poor differentiation

13 (43.33)

41 (61.19)

3.902

0.142

Moderate differentiation

15 (50.00)

23 (34.33)

High differentiation

2 (6.67)

3 (4.48)

c-Met expression

Low expression

16 (53.33)

18 (26.87)

7.929

0.005

High expression

14 (46.67)

49 (73.13)

HER2-IHC

Negative

29 (96.67)

58 (89.23)

1.913

0.167

Positive

1 (3.33)

7 (10.77)

AFP (ng/ml)

< 2.54

7 (28.00)

17 (32.08)

8.92

0.002

≥ 2.54

18 (72.00)

36 (67.92)

CEA (ng/ml)

< 2.13

11 (44.00)

28 (52.83)

0.845

0.358

≥ 2.13

14 (56.00)

25 (47.17)

CA199 (μ/ml)

< 12.78

13 (52.00)

15 (28.30)

0.448

0.503

≥ 12.78

12 (48.00)

38 (71.70)

CA153 (μ/ml)

< 7.70

15 (60.00)

23 (44.23)

1.023

0.312

≥ 7.70

10 (40.00)

29 (55.77)

CA125 (μ/ml)

< 6.80

13 (54.17)

25 (47.17)

0.055

0.814

≥ 6.80

11 (45.83)

28 (52.83)

CA50 (μ/ml)

< 4.53

12 (50.00)

25 (49.02)

0.137

0.711

≥ 4.53

12 (50.00)

26 (50.98)

H. pylori

Negative

10 (45.45)

27 (51.92)

0.427

0.514

Positive

12 (54.55)

25 (48.08)